Pfizer Looks Outside U.S. Despite New Tax Rules

The video discusses the impact of US efforts to restrict tax inversions, focusing on recent rules announced by Jack Lew. These rules aim to limit the benefits of inversions for American companies, though they leave core advantages largely intact. The discussion includes potential deals involving companies like Pfizer and Actavis, market reactions, and the strategic nature of these deals. The video also covers the implications of new rules on accessing offshore cash and the need for stronger congressional action to fully address inversion issues.

What is the main limitation of the US executive branch in restricting corporate inversions?

• Opposition from foreign governments

• Need for congressional action

• Insufficient financial resources

• Lack of public support

Why are companies like Pfizer interested in moving offshore?

• To diversify their product lines

• To increase their workforce

• To benefit from tax advantages

• To access new markets

What is a key factor for a deal to go through according to the discussion on Pfizer and Actavis?

• High market share

• Government approval

• A willing seller

• Public support

What is the primary focus of the new rules announced regarding corporate inversions?

• Future profits

• Offshore cash treatment

• Employee benefits

• Environmental regulations

What is a major complication for deals that have not yet closed under the new rules?

• Stronger congressional action

• Absence of retroactive measures

• Lack of investor interest

• Increased competition